Covered recipient · General Payments record
IRINA G ROSEWATER
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$14,687.47
- Reported across 1,069 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $623.18 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $182.00 | 13 |
| Insulet Corporation | $87.24 | 4 |
| Abbott Laboratories | $74.69 | 4 |
| Amgen Inc. | $69.95 | 3 |
| Novo Nordisk AS | $52.06 | 3 |
| ABBVIE INC. | $33.76 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.75 | 1 |
| Almatica Pharma Inc. | $26.48 | 1 |
| Medtronic, Inc. | $24.78 | 1 |
| IBSA Pharma Inc. | $24.52 | 1 |
| Xeris Pharmaceuticals, Inc. | $20.95 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.74 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085781 | CMS |
| Abbott Laboratories | $17.45 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085783 | CMS |
| Abbott Laboratories | $19.59 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085785 | CMS |
| Abbott Laboratories | $13.91 | 11/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125085787 | CMS |
| ABBVIE INC. | $20.54 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105977144 | CMS |
| ABBVIE INC. | $13.22 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105977146 | CMS |
| Almatica Pharma LLC | $26.48 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137577251 | CMS |
| Amgen Inc. | $21.02 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111692530 | CMS |
| Amgen Inc. | $26.01 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111692526 | CMS |
| Amgen Inc. | $22.92 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111692528 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.75 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118026565 | CMS |
| IBSA Pharma Inc. | $24.52 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142977934 | CMS |
| Insulet Corporation | $21.72 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116794257 | CMS |
| Insulet Corporation | $21.95 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116794253 | CMS |
| Insulet Corporation | $21.72 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116813236 | CMS |
| Insulet Corporation | $21.85 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116827648 | CMS |
| Lilly USA, LLC | $29.97 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135035248 | CMS |
| Lilly USA, LLC | $4.00 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135011321 | CMS |
| Lilly USA, LLC | $15.81 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135029496 | CMS |
| Lilly USA, LLC | $17.53 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134986852 | CMS |
| Lilly USA, LLC | $9.72 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135010251 | CMS |
| Lilly USA, LLC | $15.05 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135011323 | CMS |
| Lilly USA, LLC | $10.53 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134986854 | CMS |
| Lilly USA, LLC | $10.19 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135035250 | CMS |
| Lilly USA, LLC | $16.02 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135029498 | CMS |
| Lilly USA, LLC | $7.96 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135010655 | CMS |
| Lilly USA, LLC | $16.04 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135010657 | CMS |
| Lilly USA, LLC | $21.75 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135010249 | CMS |
| Lilly USA, LLC | $7.43 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135029500 | CMS |
| Medtronic, Inc. | $24.78 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119337614 | CMS |
| Novo Nordisk Inc | $14.58 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096656693 | CMS |
| Novo Nordisk Inc | $19.63 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096904007 | CMS |
| Novo Nordisk Inc | $17.85 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097328348 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.95 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144596942 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.